Novartis del-desiran Phase III study misses primary endpoint
- Phase III HARBOR study for del-desiran in DM1 missed primary endpoint of video hand opening time
- Secondary endpoints showed evidence of clinical activity with consistent safety profile
- Company maintains 5-6% five-year sales CAGR guidance for 2025-2030
- Other AOC assets advance with FDA priority review for DMD44 and planned meeting for FSHD
*this image is generated using AI for illustrative purposes only.
Novartis announced that its global Phase III HARBOR study evaluating del-desiran for myotonic dystrophy type 1 (DM1) did not meet its primary endpoint. The trial failed to demonstrate statistically significant improvement versus placebo on video hand opening time, a measure of hand myotonia.
Novartis reported evidence of clinical activity in secondary endpoints and exploratory analyses. Safety findings were generally consistent with previously reported data. The company is evaluating the full dataset to determine the appropriate development path.
Pipeline Progress
Despite the setback, Novartis continues to advance its antibody oligonucleotide conjugate (AOC) pipeline. The company secured FDA priority review for delpacibart zotadirsen in Duchenne muscular dystrophy with exon 44 skipping mutations. It also plans an FDA meeting for delpacibart braxlosiran in facioscapulohumeral muscular dystrophy based on positive Phase I/II biomarker data.
Financial Guidance
Novartis maintained its five-year sales compound annual growth rate (CAGR) guidance of 5-6% for 2025-2030. This outlook remains unchanged despite the clinical trial outcome.
What the Numbers Show
The divergence between the missed primary endpoint and positive secondary signals suggests complex disease biology. While vHOT failed to show statistical significance, exploratory analyses indicated some clinical activity. This pattern implies that while the drug may have biological effect, it may not sufficiently address the specific motor function metric used as the primary success criterion in this trial design.
Historical Stock Returns for Novartis
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +11.12% | +17.22% | +13.20% | 0.0% | 0.0% | +117.57% |
How might Novartis' decision to pivot the del-desiran development path impact its overall strategy for treating myotonic dystrophy type 1?
What are the potential regulatory risks for delpacibart zotadirsen during its FDA priority review, given the recent setback in the broader AOC pipeline?
Could the mixed results from the HARBOR study influence investor confidence in Novartis' ability to maintain its 5-6% sales CAGR guidance through 2030?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
